201 related articles for article (PubMed ID: 33576627)
1. Unique Molecular Interaction with the Histone Deacetylase 6 Catalytic Tunnel: Crystallographic and Biological Characterization of a Model Chemotype.
Olaoye OO; Watson PR; Nawar N; Geletu M; Sedighi A; Bukhari S; Raouf YS; Manaswiyoungkul P; Erdogan F; Abdeldayem A; Cabral AD; Hassan MM; Toutah K; Shouksmith AE; Gawel JM; Israelian J; Radu TB; Kachhiyapatel N; de Araujo ED; Christianson DW; Gunning PT
J Med Chem; 2021 Mar; 64(5):2691-2704. PubMed ID: 33576627
[TBL] [Abstract][Full Text] [Related]
2. PTG-0861: A novel HDAC6-selective inhibitor as a therapeutic strategy in acute myeloid leukaemia.
Gawel JM; Shouksmith AE; Raouf YS; Nawar N; Toutah K; Bukhari S; Manaswiyoungkul P; Olaoye OO; Israelian J; Radu TB; Cabral AD; Sina D; Sedighi A; de Araujo ED; Gunning PT
Eur J Med Chem; 2020 Sep; 201():112411. PubMed ID: 32615502
[TBL] [Abstract][Full Text] [Related]
3. Exploring Structural Determinants of Inhibitor Affinity and Selectivity in Complexes with Histone Deacetylase 6.
Osko JD; Porter NJ; Narayana Reddy PA; Xiao YC; Rokka J; Jung M; Hooker JM; Salvino JM; Christianson DW
J Med Chem; 2020 Jan; 63(1):295-308. PubMed ID: 31793776
[TBL] [Abstract][Full Text] [Related]
4. The structural requirements of histone deacetylase inhibitors: C4-modified SAHA analogs display dual HDAC6/HDAC8 selectivity.
Negmeldin AT; Knoff JR; Pflum MKH
Eur J Med Chem; 2018 Jan; 143():1790-1806. PubMed ID: 29150330
[TBL] [Abstract][Full Text] [Related]
5. Binding of inhibitors to active-site mutants of CD1, the enigmatic catalytic domain of histone deacetylase 6.
Osko JD; Christianson DW
Acta Crystallogr F Struct Biol Commun; 2020 Sep; 76(Pt 9):428-437. PubMed ID: 32880591
[TBL] [Abstract][Full Text] [Related]
6. Unusual zinc-binding mode of HDAC6-selective hydroxamate inhibitors.
Porter NJ; Mahendran A; Breslow R; Christianson DW
Proc Natl Acad Sci U S A; 2017 Dec; 114(51):13459-13464. PubMed ID: 29203661
[TBL] [Abstract][Full Text] [Related]
7. Structural determinants of affinity and selectivity in the binding of inhibitors to histone deacetylase 6.
Osko JD; Christianson DW
Bioorg Med Chem Lett; 2020 Apr; 30(8):127023. PubMed ID: 32067866
[TBL] [Abstract][Full Text] [Related]
8. Design, synthesis, and biological evaluation of indole-based hydroxamic acid derivatives as histone deacetylase inhibitors.
Jiang BE; Hu J; Liu H; Liu Z; Wen Y; Liu M; Zhang HK; Pang X; Yu LF
Eur J Med Chem; 2022 Jan; 227():113893. PubMed ID: 34656899
[TBL] [Abstract][Full Text] [Related]
9. Synthesis and Biological Investigation of Phenothiazine-Based Benzhydroxamic Acids as Selective Histone Deacetylase 6 Inhibitors.
Vögerl K; Ong N; Senger J; Herp D; Schmidtkunz K; Marek M; Müller M; Bartel K; Shaik TB; Porter NJ; Robaa D; Christianson DW; Romier C; Sippl W; Jung M; Bracher F
J Med Chem; 2019 Feb; 62(3):1138-1166. PubMed ID: 30645113
[TBL] [Abstract][Full Text] [Related]
10. Investigation of the effect of different linker chemotypes on the inhibition of histone deacetylases (HDACs).
Linciano P; Benedetti R; Pinzi L; Russo F; Chianese U; Sorbi C; Altucci L; Rastelli G; Brasili L; Franchini S
Bioorg Chem; 2021 Jan; 106():104462. PubMed ID: 33213894
[TBL] [Abstract][Full Text] [Related]
11. Structure-based design generated novel hydroxamic acid based preferential HDAC6 lead inhibitor with on-target cytotoxic activity against primary choroid plexus carcinoma.
Kassab SE; Mowafy S; Alserw AM; Seliem JA; El-Naggar SM; Omar NN; Awad MM
J Enzyme Inhib Med Chem; 2019 Dec; 34(1):1062-1077. PubMed ID: 31072216
[TBL] [Abstract][Full Text] [Related]
12. Development of HDAC Inhibitors Exhibiting Therapeutic Potential in T-Cell Prolymphocytic Leukemia.
Toutah K; Nawar N; Timonen S; Sorger H; Raouf YS; Bukhari S; von Jan J; Ianevski A; Gawel JM; Olaoye OO; Geletu M; Abdeldayem A; Israelian J; Radu TB; Sedighi A; Bhatti MN; Hassan MM; Manaswiyoungkul P; Shouksmith AE; Neubauer HA; de Araujo ED; Aittokallio T; Krämer OH; Moriggl R; Mustjoki S; Herling M; Gunning PT
J Med Chem; 2021 Jun; 64(12):8486-8509. PubMed ID: 34101461
[TBL] [Abstract][Full Text] [Related]
13. Isoindoline scaffold-based dual inhibitors of HDAC6 and HSP90 suppressing the growth of lung cancer in vitro and in vivo.
Ojha R; Nepali K; Chen CH; Chuang KH; Wu TY; Lin TE; Hsu KC; Chao MW; Lai MJ; Lin MH; Huang HL; Chang CD; Pan SL; Chen MC; Liou JP
Eur J Med Chem; 2020 Mar; 190():112086. PubMed ID: 32058238
[TBL] [Abstract][Full Text] [Related]
14. Structural insights into HDAC6 tubulin deacetylation and its selective inhibition.
Miyake Y; Keusch JJ; Wang L; Saito M; Hess D; Wang X; Melancon BJ; Helquist P; Gut H; Matthias P
Nat Chem Biol; 2016 Sep; 12(9):748-54. PubMed ID: 27454931
[TBL] [Abstract][Full Text] [Related]
15. Histone Deacetylase 6-Selective Inhibitors and the Influence of Capping Groups on Hydroxamate-Zinc Denticity.
Porter NJ; Osko JD; Diedrich D; Kurz T; Hooker JM; Hansen FK; Christianson DW
J Med Chem; 2018 Sep; 61(17):8054-8060. PubMed ID: 30118224
[TBL] [Abstract][Full Text] [Related]
16. Structure-activity relationship study of thiazolyl-hydroxamate derivatives as selective histone deacetylase 6 inhibitors.
Nam G; Jung JM; Park HJ; Baek SY; Baek KS; Mok HY; Kim DE; Jung YH
Bioorg Med Chem; 2019 Aug; 27(15):3408-3420. PubMed ID: 31235266
[TBL] [Abstract][Full Text] [Related]
17. Design and Synthesis of Dihydroxamic Acids as HDAC6/8/10 Inhibitors.
Morgen M; Steimbach RR; Géraldy M; Hellweg L; Sehr P; Ridinger J; Witt O; Oehme I; Herbst-Gervasoni CJ; Osko JD; Porter NJ; Christianson DW; Gunkel N; Miller AK
ChemMedChem; 2020 Jul; 15(13):1163-1174. PubMed ID: 32348628
[TBL] [Abstract][Full Text] [Related]
18. Selective Inhibition of Histone Deacetylase 10: Hydrogen Bonding to the Gatekeeper Residue is Implicated.
Géraldy M; Morgen M; Sehr P; Steimbach RR; Moi D; Ridinger J; Oehme I; Witt O; Malz M; Nogueira MS; Koch O; Gunkel N; Miller AK
J Med Chem; 2019 May; 62(9):4426-4443. PubMed ID: 30964290
[TBL] [Abstract][Full Text] [Related]
19. Methods for the expression, purification, and crystallization of histone deacetylase 6-inhibitor complexes.
Osko JD; Christianson DW
Methods Enzymol; 2019; 626():447-474. PubMed ID: 31606087
[TBL] [Abstract][Full Text] [Related]
20. Discovery of Novel Histone Deacetylase 6 (HDAC6) Inhibitors with Enhanced Antitumor Immunity of Anti-PD-L1 Immunotherapy in Melanoma.
Peng X; Li L; Chen J; Ren Y; Liu J; Yu Z; Cao H; Chen J
J Med Chem; 2022 Feb; 65(3):2434-2457. PubMed ID: 35043615
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
